Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acitretin
Drug ID BADD_D00036
Description An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.
Indications and Usage Zouboulis CC: Retinoids--which dermatological indications will benefit in the near future? Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15.
Marketing Status Prescription; Discontinued
ATC Code D05BB02
DrugBank ID DB00459
KEGG ID D02754
MeSH ID D017255
PubChem ID 5284513
TTD Drug ID D05QDC
NDC Product Code 42291-088; 0145-0091; 17337-0004; 76055-0001; 71214-0668; 0093-1136; 0093-1135; 58159-058; 42794-081; 42794-080; 0093-1138; 0145-0090; 62147-0145; 42794-083; 42291-086; 71214-0667; 71214-0669; 0378-7020; 0115-1750; 0115-1751; 0115-1752; 71214-0698; 42291-087; 62147-0146; 0378-7023; 17337-0003; 59981-011; 0115-1753
Synonyms Acitretin | Etretin | Isoacitretin | Isoetretin | Ro 10-1670 | Ro 101670 | Ro-10-1670 | Ro101670 | 13-cis-Acitretin | Neotigason | Soriatane | Acitretin, (Z,E,E,E)-Isomer | Ro-13-7652 | Ro137652 | Ro 13-7652 | Ro 137652
Chemical Information
Molecular Formula C21H26O3
CAS Registry Number 55079-83-9
SMILES CC1=CC(=C(C(=C1C=CC(=CC=CC(=CC(=O)O)C)C)C)C)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemorrhage24.07.01.002--Not Available
Rectal tenesmus07.03.03.001; 15.05.03.011--Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.005728%
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Congenital eye disorder06.08.03.011; 03.01.01.002--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.0040.005728%
Hepatic enzyme increased13.03.01.0190.005728%Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Embolism24.01.01.009--
Upper limb fracture15.08.03.018; 12.04.01.0180.005728%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Renal function test abnormal13.13.01.0120.005728%Not Available
Ill-defined disorder08.01.03.049--Not Available
Lacrimal disorder06.08.02.005--Not Available
Occult blood13.05.02.003--Not Available
Hyperlipidaemia14.08.03.001--
Urine analysis abnormal13.13.02.008--Not Available
Renal impairment20.01.03.0100.014320%Not Available
Self injurious behaviour19.12.01.005--Not Available
Skin haemorrhage24.07.06.009; 23.06.07.0010.008592%Not Available
Ulcerative keratitis06.04.02.004; 10.02.01.021--
Acute promyelocytic leukaemia differentiation syndrome12.03.01.042; 22.02.01.0230.008592%
Cytopenia01.03.03.012--Not Available
Treatment failure08.06.01.0170.002241%Not Available
Skin mass23.07.04.014--Not Available
Intellectual disability19.21.06.001; 17.03.07.0010.005728%Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages